




RESEARCH REPORT MARCH 2019



Immuno-Oncology Diagnostics

The Race for Biomarkers

Market Forecasts for Immuno-Oncology Diagnostics. With Executive and Consultant Guides and including Customized Forecasting and Analysis.

2019 to 2023



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- i. Market Guides 14
 - iA. Situation Analysis 15
 - iB. Guide for Executives and Marketing Staff 17
 - iC. Guide for Investment Analysts and Management Consultants 18
 - iD. Impact of the Nobel Prize 19
- 1. Introduction and Market Definition 20
 - 1.1 What are Immuno-Oncology Diagnostics?21
 - 1.2 Immuno-oncology – the looming cure 22
 - 1.2.1 Immuno-oncology Diagnostics Takes a Leading Role 24
 - 1.3 Market Definition 24
 - 1.3.1 Market Size 25
 - 1.3.2 Currency 25
 - 1.3.3 Years 25
 - 1.4 Methodology 26
 - 1.4.1 Authors 26
 - 1.4.2 Sources 26
 - 1.5 U.S. Medical Market and laboratory Testing - Perspective26
 - 1.4.1 U.S. Medicare Expenditures for Laboratory Testing 27
- 2. Immunotherapy – Guide to Immune Technologies 29
 - 2.0 The Immune System 30
 - 2.0.1 Innate immune system 31
 - 2.0.1.1 Surface barriers 31
 - 2.0.1.2 Inflammation 32
 - 2.0.1.3 Complement system 33

- 2.0.1.4 Cellular barriers 33
- 2.0.1.5 Natural killer cells 34
- 2.0.2 Adaptive immune system..... 35
 - 2.0.2.1 Lymphocytes..... 35
 - 2.0.2.2 Killer T cells 35
 - 2.0.2.3 Helper T cells 37
 - 2.0.2.4 Gamma delta T cells..... 38
 - 2.0.2.5 B lymphocytes and antibodies 38
- 2.0.3 Tumor immunology – the immune surveillance system 40
- 2.1 Immuno OncologyDiagnostics42
 - 2.1.1 Checkpoint Assays..... 42
 - 2.1.1.1 Outlook for Checkpoint Assays 46
 - 2.1.2 Cytokine Assays 46
 - 2.1.2.1 Outlook for Cytokine Assays 47
 - 2.1.3 Genomic Germline..... 47
 - 2.1.3.1 Outlook for Genomic Germline 48
 - 2.1.4 Genomic Tumour..... 48
 - 2.1.4.1 Outlook for Genomic Tumour 50
 - 2.1.5 Tumor Microenviroment 51
 - 2.1.5.1 Outlook for Tumor Micro Environment 52
 - 2.1.6 Others 52
 - 2.1.6.1 Outlook for Other Diagnostics 52
- 3. Industry Overview..... 53
 - 3.1 Players in a Dynamic Market..... 54
 - 3.1.1 Academic Research Lab 54
 - 3.1.2 Diagnostic Test Developer..... 55
 - 3.1.3 Genomic Instrumentation Supplier..... 55

- 3.1.3.1 Cell Separation and Viewing Instrumentation Supplier 55
- 3.1.4 Pharmaceutical/Reagent Supplier 55
- 3.1.5 Independent Testing Lab 55
- 3.1.6 Public National/regional lab 56
- 3.1.7 Hospital lab 56
- 3.1.8 Physician Lab..... 56
- 3.1.9 Audit Body..... 56
- 3.1.10 Certification Body..... 57
- 4. Market Trends 58
 - 4.1 Factors Driving Growth..... 59
 - 4.1.1 Outcome potential 59
 - 4.1.2 Companion Diagnostics..... 60
 - 4.1.3 Funding..... 60
 - 4.1.4 Technology Environment 60
 - 4.1.5 Target Solutions..... 61
 - 4.2 Factors Limiting Growth 62
 - 4.2.1 Complex Role of Diagnostics 62
 - 4.2.2 Clinical Trials Role..... 63
 - 4.2.3 Protocols..... 63
 - 4.3 Diagnostic Technology Development64
 - 4.3.1 Combinations - Issues and Complexity 64
 - 4.3.2 Shifting Role of Diagnostics..... 65
 - 4.3.3 Multiplexing and Foundation One 66
 - 4.3.4 The Disruption Dynamic 66
 - 4.3.5 The Race for Biomarkers 67
 - 4.3.6 The Next Five Years 68
- 5. Cancer Immunotherapy Recent Developments 69

| | |
|---|----|
| 5.1 Recent Developments – Importance and How to Use This Section..... | 70 |
| 5.1.1 Importance of These Developments | 70 |
| 5.1.2 How to Use This Section | 70 |
| Icon Acquires MolecularMD..... | 70 |
| Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca | 71 |
| Tumor Mutational Burden as Predictor of Immunotherapy Success..... | 72 |
| Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda | 74 |
| Abcam Acquires Calico Biolabs..... | 75 |
| Cancer Genetics and NovellusDx to Merge..... | 76 |
| ApoCell Expands Immuno-Oncology Biomarker Services..... | 77 |
| MRM Proteomics Inc and Exactis Innovation Partner | 79 |
| Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma..... | 80 |
| Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution..... | 81 |
| MolecularMD Launches Validated Tumor Mutation Burden Assay..... | 82 |
| Minomic Secures Key Patent in the United States and China | 83 |
| Biocartis and Wondfo Announce Joint Venture | 84 |
| Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics | 84 |
| Cancer Genetics Expands Immuno-Oncology Panel..... | 85 |
| 10x Genomics Acquires Epinomics, To Launch ATAC-Seq Product | 87 |
| Qiagen, Freenome Partner to Improve Companion Diagnostic Development | 88 |
| Personal Genome Diagnostics to Develop Companion Diagnostic for Five Prime | 88 |
| Thermo Fisher Expands OncoPrint Immuno-Oncology Assay Portfolio..... | 90 |
| Bristol-Myers Squibb and Illumina to Develop Companion Diagnostics for Oncology Immunotherapies.... | 90 |
| HalioDx announces high capacity IHC multiplex technology..... | 91 |
| MolecularMD to Implement Promega’s Technology..... | 92 |
| NCI, NanoString Collaborate to Evaluate Utility of PanCancer Gene Expression Panel | 93 |
| MIODx to Develop Immune Repertoire Sequencing Assay to Predict Immunotherapy Response | 94 |

Personal Genome Diagnostics Licenses Tumor Mutation Burden from MSKCC..... 96

HaliuDx Closes €18.5M Series B Round 96

Announcement of the 2018 Nobel Prize in Physiology or Medicine..... 97

6. Profiles of Key Immunotherapy Companies 100

10X Genomics 101

Abbott Laboratories..... 102

Abcam 104

Adaptive Biotechnologies 105

Aethlon Medical 106

Agena Bioscience 107

Angle plc 109

Apocell 110

ARUP Laboratories 111

Beckman Coulter..... 113

Becton Dickinson 114

Bioarray Genetics 116

BioCartis..... 117

Biocept 118

Biodesix Inc..... 119

BioFluidica 120

Biolidics (previously Clearbridge BioMedics) 121

bioMérieux 122

Bio-Rad 123

Bio-Techne 124

Bristol-Myers Squibb 125

Cancer Genetics..... 126

Caris Molecular Diagnostics 127

| | |
|-----------------------------------|-----|
| CellMax Life | 128 |
| Charles River | 129 |
| Chronix Biomedical | 130 |
| Circulogene | 131 |
| Clinical Genomics | 133 |
| Cynvenio | 134 |
| Cytolumina Technologies Corp..... | 135 |
| CytoTrack..... | 136 |
| Dako (Agilent)..... | 137 |
| Diagnologix LLC | 139 |
| Epic Sciences..... | 140 |
| Exosome Diagnostics | 141 |
| Fluidigm Corp | 142 |
| Fluxion Biosciences | 143 |
| Foundation Medicine..... | 144 |
| Freenome | 145 |
| Genomic Health..... | 146 |
| GenomOncology | 147 |
| GRAIL..... | 148 |
| Guardant Health | 149 |
| HalioDx | 150 |
| Horizon Discovery | 151 |
| HTG Molecular Diagnostics..... | 152 |
| iCellate | 154 |
| Illumina | 155 |
| Incell Dx..... | 156 |

| | |
|----------------------------------|-----|
| Inivata..... | 157 |
| Integrated Diagnostics..... | 158 |
| Invivoscribe..... | 159 |
| Leica Biosystems..... | 160 |
| Luminex..... | 161 |
| MDx Health..... | 162 |
| Merck & Co., Inc..... | 163 |
| MIODx..... | 164 |
| Molecular MD..... | 165 |
| MRM Proteomics Inc..... | 166 |
| Myriad Genetics/Myriad RBM..... | 167 |
| Nanostring..... | 168 |
| Natera..... | 169 |
| Neogenomics..... | 170 |
| New Oncology..... | 171 |
| Oncocyte..... | 172 |
| Ortho Clinical Diagnostics..... | 173 |
| Perkin Elmer..... | 174 |
| Personal Genome Diagnostics..... | 175 |
| Pfizer..... | 176 |
| Promega..... | 178 |
| Protagen Diagnostics..... | 180 |
| Qiagen..... | 181 |
| Quanterix..... | 183 |
| Rarecells SAS..... | 184 |
| Roche Diagnostics..... | 185 |
| Siemens..... | 187 |

| | |
|---|-----|
| Silicon Biosystems | 188 |
| SkylineDx..... | 189 |
| SRI International | 190 |
| Sysmex | 191 |
| Thermo Fisher | 192 |
| Trovogene..... | 194 |
| Vortex Biosciences..... | 195 |
| 7. Global Market Size..... | 196 |
| 7.1 Immuno-oncology Diagnostics Global Market Size by Country with Charts | 197 |
| 7.2 Immuno-oncology Diagnostics Global Market Size by Type with Charts | 199 |
| 8. Global Market by Type | 201 |
| 8.1 Checkpoint Assay Market | 202 |
| 8.1.1 Checkpoint Assay Market by Country with Chart..... | 202 |
| 8.2 Cytokine Assay Market | 204 |
| 8.2.1 Cytokine Assay Market by Country with Chart..... | 204 |
| 8.3 Genome Germline Market..... | 206 |
| 8.3.1 Genome Germline Market by Country with Chart..... | 206 |
| 8.4 Genome Tumour Market | 208 |
| 8.4.1 Genome Tumour Market by Country with Chart..... | 208 |
| 8.5 Tumour Micro Environment Market | 210 |
| 8.5.1 Tumour Micro Environment Market by Country with Chart..... | 210 |
| 8.6 Other Market..... | 212 |
| 8.6.1 Other Market by Country with Chart | 212 |
| 9. Appendices..... | 214 |
| 9.1 FDA Cancer Drug Approvals by Year..... | 215 |
| 9.2 Clinical Trials Started 2010 to 2016..... | 216 |
| 9.3 Prevalence of Cancer Treatments – 2015 | 217 |

Table of Tables

Table 1 List of Cancers by Mortality 23

Table 2 Lab Spending 2014 to 2024..... 28

Table 3 Overview of Innate and Adaptive Immunity 31

Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment 43

Table 5 FDA Approved Companion diagnostics in Cancer treatment 48

Table 6 Market Players by Type..... 54

Table 7 Five Factors Driving Growth 59

Table 8 Three Factors Limiting Growth 62

Table 9 Immuno-oncology Diagnostics Global Market by Country/Region 197

Table 10 Immuno-oncology Diagnostics Global Market by Type..... 199

Table 11 Checkpoint Assay Market by Country..... 202

Table 12 Cytokine Assay Market by Country..... 204

Table 13 Genome Germline Market by Country..... 206

Table 14 Genome Tumour Market by Country..... 208

Table 15 Tumour Micro Environment Market by Country 210

Table 16 Other Market by Country 212

Table of Figures

Figure 1 Cancer Death Rates –USA, CDC 22

| | |
|--|-----|
| Figure 2 Clinical Lab Spending 2014 to 2024..... | 27 |
| Figure 3 Helper T Cell Roles..... | 37 |
| Figure 4 Antibody Diagram | 39 |
| Figure 5 Macrophages attack a Cancer Cell | 40 |
| Figure 6 The Tumour Micro Environment..... | 51 |
| Figure 7 Comparing IO Diagnostic and Traditional Testing..... | 65 |
| Figure 8 Growth rates of IO Diagnostic Technologies..... | 68 |
| Figure 9 Market Size by Country - Key Countries..... | 198 |
| Figure 10 Global Market by Country | 198 |
| Figure 11 Chart of Global Market by Type..... | 199 |
| Figure 12 Growth Rates of Diagnostic Segments..... | 200 |
| Figure 13 IO Diagnostics Share Change by Type | 200 |
| Figure 14 Chart – Checkpoint Assay Market by Country | 203 |
| Figure 15 Chart – Cytokine Assay Market by Country | 205 |
| Figure 16 Chart – Genome Germline Market by Country..... | 207 |
| Figure 17 Chart - Genome Tumour Market by Country..... | 209 |
| Figure 18 Chart – Tumour Micro Environment Market by Country | 211 |
| Figure 19 Chart – Other Market, Global Size..... | 213 |
| Figure 20 FDA Cancer Drug Approvals by Year | 215 |
| Figure 21 Clinical Trials for Immunotherapy by Year | 216 |
| Figure 22 Pie Chart of Prevalence of Cancer Treatments | 217 |